PHCCC

Из Википедије, слободне енциклопедије
PHCCC
(IUPAC) ime
(-)-N-fenil-7-(hidroksimino)ciklopropa[b]hromen-1a-karboksamid
Klinički podaci
Identifikatori
ATC kod nije dodeljen
PubChem[1][2] 3579925
Hemijski podaci
Formula C17H14N2O3 
Mol. masa 294,304 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

PHCCC je istraživački lek koji deluje kao ligand glutamatnog receptora. On je pozitivni alosterni modulator mGluR4 podtipa,[3] kao i agonist mGluR6.[4] On ispoljava anksiolitičko dejstvo u životinjskim studijama.[5] PHCCC i slični lekovi su potencijalne nove terapije za Parkinsonovu bolest.[6]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Maj M, Bruno V, Dragic Z, Yamamoto R, Battaglia G, Inderbitzin W, Stoehr N, Stein T, Gasparini F, Vranesic I, Kuhn R, Nicoletti F, Flor PJ (December 2003). „(-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection“. Neuropharmacology 45 (7): 895–906. DOI:10.1016/S0028-3908(03)00271-5. PMID 14573382. 
  4. ^ Beqollari D, Kammermeier PJ (July 2008). „The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors“. European Journal of Pharmacology 589 (1–3): 49–52. DOI:10.1016/j.ejphar.2008.06.054. PMID 18593581. 
  5. ^ Stachowicz K, Kłak K, Kłodzińska A, Chojnacka-Wojcik E, Pilc A (September 2004). „Anxiolytic-like effects of PHCCC, an allosteric modulator of mGlu4 receptors, in rats“. European Journal of Pharmacology 498 (1–3): 153–6. DOI:10.1016/j.ejphar.2004.07.001. PMID 15363989. 
  6. ^ Niswender CM, Johnson KA, Weaver CD, Jones CK, Xiang Z, Luo Q, Rodriguez AL, Marlo JE, de Paulis T, Thompson AD, Days EL, Nalywajko T, Austin CA, Williams MB, Ayala JE, Williams R, Lindsley CW, Conn PJ (November 2008). „Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4“. Molecular Pharmacology 74 (5): 1345–58. DOI:10.1124/mol.108.049551. PMC 2574552. PMID 18664603. 

Vidi još[уреди]

Spoljašnje veze[уреди]